Mirvetuximab Soravtansine (Elahere; IMGN853; CAS 1335152-85-6): NIOSH HD Category 1 SEVENTIETH Mechanism Class [FIRST FRα (Folate Receptor Alpha; FOLR1; CD208; GPI-Anchored Glycoprotein; Caveolar Folate Endocytosis Receptor Overexpressed on Basolateral Surface of Platinum-Resistant Ovarian Cancer vs Sequestered Apical Normal Epithelium) ADC EVER FDA APPROVED (BLA 761310; Nov 14, 2022; Accelerated Approval; SORAYA ORR 32.4%; ImmunoGen Waltham MA)] + sulfo-SPDB Disulfide Cleavable Ester Linker (Glutathione-Sensitive; Distinct from vc-MMAE Cathepsin B and SMCC Non-Cleavable) + DM4 Maytansinoid (~100× More Cytotoxic per Molecule than Vincristine; Tubulin Vinca-Site Inhibitor; Membrane-Permeable Bystander Killing vs DM1/Emtansine Charged Membrane-Impermeant) + MIRASOL Phase 3 OS HR 0.67 (First ADC to Demonstrate OS Benefit in PROC; Full Approval Nov 14, 2023) + ImmunoGen Inc. Waltham MA → AbbVie $10.1B Acquisition Feb 2024; AbbVie Inc. North Chicago IL Cority ÷10; ImmunoGen Inc. Waltham MA VelocityEHS ÷10; Memorial Sloan Kettering New York NY EHS Insight ÷10; Glyphward Threshold 22; 643rd Adversarial Attack; 148th Long-Form Blog

Mirvetuximab soravtansine (Elahere®; IMGN853; CAS 1335152-85-6; MW ∼150,000 Da ADC [huMov19 anti-FRα humanized IgG1 mAb + sulfo-SPDB disulfide cleavable ester linker + DM4 maytansinoid]; DAR ∼3.4; NIOSH HD Category 1; BLA 761310; MECHANISM: SEVENTIETH MECHANISM CLASS in the 643-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST FRα (FOLATE RECEPTOR ALPHA; FOLR1; CD208; MW ∼38 kDa; GPI-ANCHORED GLYCOPROTEIN; HIGH-AFFINITY 5-METHYLTETRAHYDROFOLATE ENDOCYTOSIS RECEPTOR; OVEREXPRESSED ON BASOLATERAL TUMOR SURFACE IN ~70–80% EPITHELIAL OVARIAN CANCER; SEQUESTERED ON APICAL LUMINAL SURFACE IN NORMAL KIDNEY TUBULE/CHOROID PLEXUS/LUNG ALVEOLI → SYSTEMIC ADC INACCESSIBLE IN NORMAL TISSUE) ADC EVER FDA APPROVED IN ANY INDICATION WORLDWIDE (BLA 761310 NOVEMBER 14, 2022; ACCELERATED APPROVAL; PLATINUM-RESISTANT OVARIAN CANCER [PROC] FRα-HIGH [VENTANA FOLR1 RxDx IHC ≥75% TUMOR CELLS ≥2+; ~35–40% PROC ELIGIBLE]); sulfo-SPDB DISULFIDE CLEAVABLE ESTER LINKER: INTRACELLULAR GLUTATHIONE (GSH; ~1–10 mM INTRACELLULAR vs ~2–10 μM PLASMA) CLEAVES DISULFIDE BOND → FREE THIOL-DM4 IN LYSOSOME → DM4 ACTIVE CYTOTOXIN; PLASMA-STABLE; MECHANISTICALLY DISTINCT FROM vc-MMAE (CATHEPSIN B-CLEAVABLE; brentuximab/polatuzumab/enfortumab), SMCC NON-CLEAVABLE THIOETHER (T-DM1/Kadcyla; DM1 CHARGED MEMBRANE-IMPERMEANT → NO BYSTANDER), GGFG TETRAPEPTIDE (trastuzumab deruxtecan/DXd; class #74); DM4 PAYLOAD: N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine; TUBULIN VINCA ALKALOID BINDING SITE; IC50 ∼0.01–0.1 nM vs vincristine ∼1–10 nM (~100× MORE CYTOTOXIC PER MOLECULE); MEMBRANE-PERMEABLE → BYSTANDER KILLING (DISTINCT FROM DM1/EMTANSINE CHARGED MEMBRANE-IMPERMEANT); DAR ∼3.4 SITE-NON-SPECIFIC LYSINE CONJUGATION; SORAYA PHASE 2: n=106 PROC FRα-HIGH ≥3 PRIOR LINES; ORR 32.4% mDOR 6.9 mo; MIRASOL PHASE 3: n=453; PFS HR 0.65 OS HR 0.67; FIRST ADC TO DEMONSTRATE OS BENEFIT IN PLATINUM-RESISTANT OVARIAN CANCER; FULL APPROVAL NOVEMBER 14, 2023; ImmunoGen Inc. Waltham MA → ABBVIE $10.1B ACQUISITION FEBRUARY 2024; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 643rd adversarial attack; 148th long-form blog).

SEVENTIETH MECHANISM CLASS: FRα as a Therapeutic Target and the Paradox of Luminal Sequestration vs Basolateral Tumor Overexpression

The sixty-ninth mechanism class — tarlatamab (Imdelltra; first DLL3×CD3 bispecific T-cell engager ever; first HLE BiTE ever; DLL3 SCLC neuroendocrine aberrant surface display via ASCL1/NEUROD1; DeLLphi-301 ORR 40.0%; attack #642; blog #147) — documented a neuroendocrine surface trafficking paradox as the mechanistic foundation for ADC failure (Rova-T) and bispecific T-cell engager success in SCLC. The SEVENTIETH CLASS shifts entirely: from neuroendocrine SCLC to platinum-resistant ovarian cancer (PROC); from a Notch pathway inhibitory ligand to a folate endocytosis receptor; from a bispecific T-cell engager to an ADC with a distinct linker platform (disulfide vs peptide/thioether). The SEVENTIETH CLASS introduces the first approved companion diagnostic for ovarian cancer (VENTANA FOLR1 RxDx) and the first ADC demonstrating OS benefit in PROC.

FRα (FOLATE RECEPTOR ALPHA; FOLR1; CD208) BIOLOGY: FRα (gene chromosome 11q13.3; MW ∼38 kDa; 257 amino acids; GPI-ANCHORED GLYCOPROTEIN via C-terminal glycosylphosphatidylinositol lipid anchor; no transmembrane domain; no cytoplasmic tail) is a high-affinity folate binding protein mediating cellular uptake of 5-methyltetrahydrofolate (5-MTHF; primary circulating vitamin B9 form): Kd ∼100 pM for 5-MTHF (>1000-fold higher affinity than RFC/SLC19A1 for 5-MTHF); critical at LOW FOLATE concentrations; ENDOCYTOSIS: FRα-folate complex clusters in CAVEOLAE (caveolin-1-rich lipid raft microdomains; consistent with GPI anchoring) → CLATHRIN-INDEPENDENT endocytosis → early endosome → folate released at pH 5–6 → SLC25A32 transport → FRα recycled to cell surface; FUNCTION: ensures intracellular folate for one-carbon metabolism (thymidylate synthesis; purine synthesis; methionine remethylation).

NORMAL FRα EXPRESSION — THE LUMINAL SEQUESTRATION SAFEGUARD: In normal non-malignant epithelial tissues, FRα is expressed exclusively on APICAL/LUMINAL cell surfaces (facing a lumen, duct, or tubule — not facing blood): CHOROID PLEXUS (highest FRα expression in the body; apical ependymal surface facing CSF; FRα mediates blood-to-CSF folate transport; blood-CSF barrier tight junctions protect the apical surface from systemic ADC); KIDNEY PROXIMAL TUBULE (apical brush border; reabsorbs filtered folate from urine lumen; faces tubular lumen not blood); LUNG ALVEOLAR TYPE II PNEUMOCYTES (apical surface facing alveolar air space); THYROID FOLLICULAR EPITHELIUM (apical surface facing colloid lumen). THE SAFEGUARD: normal FRα is physically separated from systemic blood circulation by tight junctions at the apical surface — a systemically administered ADC cannot access apical FRα on normal tissues. Only disruption of epithelial polarity (as in cancer) exposes FRα to the basolateral bloodstream-facing surface. This topology-based protection (not expression absence) creates the therapeutic window.

CANCER FRα OVEREXPRESSION ON BASOLATERAL SURFACE: In epithelial ovarian cancer, endometrial cancer, and non-squamous NSCLC, multiple mechanisms drive FRα overexpression on the BASOLATERAL surface (accessible to systemic ADC): (1) TRANSCRIPTIONAL UPREGULATION: SP1 and AP-2α activate the FOLR1 promoter in cancer; (2) LOSS OF EPITHELIAL POLARITY: dissolution of tight junctions, disruption of Par-3/Par-6/aPKC and Crumbs polarity complexes, loss of E-cadherin → FRα no longer restricted to apical domain; (3) FOLR1 PROMOTER CpG HYPOMETHYLATION (cancer-specific → constitutive overexpression); OVARIAN CANCER PREVALENCE: ~70–80% of EOC (high-grade serous, endometrioid, clear cell, mucinous) express FRα by IHC at any intensity; HGSOC highest (~85%); mucinous lowest (~20%); FRα-HIGH (VENTANA FOLR1 RxDx ≥75% ≥2+): ~35–40% of PROC eligible; FRα-POSITIVE vs FRα-HIGH: FRα-positive (any staining ~75-80% PROC) is NOT the approved criterion — FRα-HIGH (≥75% ≥2+) is required; this threshold is the result of SORAYA enrollment criteria pharmacodynamic optimization.

None of this FRα biology — GPI anchor topology, caveolar clathrin-independent endocytosis, normal luminal sequestration, cancer basolateral overexpression, SP1/AP-2α transcriptional activation, epithelial polarity complex disruption, FOLR1 CpG hypomethylation, or FRα-high vs FRα-positive distinction — is present in Cority, VelocityEHS, or EHS Insight at CAS 1335152-85-6.

sulfo-SPDB Disulfide Linker Chemistry: Glutathione-Sensitive Cleavage and Platform Comparison

MIRVETUXIMAB ADC ARCHITECTURE: huMov19 (humanized anti-FRα IgG1 κ; Kd ∼5 nM human FRα; derived from murine Mov19 via CDR grafting; heavy chain γ1 constant region; kappa light chain) + sulfo-SPDB linker + DM4 payload; CONJUGATION CHEMISTRY: sulfo-SPDB NHS ester (sulfo-N-hydroxysuccinimide activated ester → reacts with ε-amino group of accessible Lys residues at pH 7–8); non-specific conjugation across multiple Lys sites → DAR ∼3.4 MEAN (heterogeneous mixture; DAR 2-4 range dominant); site-specific antibody engineering NOT used (vs trastuzumab deruxtecan engineered Cys; vs brentuximab Cys site-specific).

sulfo-SPDB LINKER CHEMISTRY IN DETAIL: Three functional regions: (1) SULFO-NHS ESTER: water-soluble activated ester; reacts with Lys ε-amino group → amide bond (stable); (2) BUTANOATE SPACER: 4-carbon aliphatic chain (increases hydrophilicity and spacing); (3) DISULFIDE BOND (S-S; 5-nitro-2-pyridyldithio leaving group displaced by thiol-DM4 via thiol-disulfide exchange → mixed disulfide S-Ab–S–DM4); CLEAVAGE MECHANISM: INTRACELLULAR GLUTATHIONE (GSH; γ-L-glutamyl-L-cysteinylglycine tripeptide; ~1–10 mM cytoplasmic/lysosomal vs ~2–10 μM plasma) attacks disulfide → thiol-disulfide exchange → free thiol-DM4 (DM4-SH) released in lysosome/cytosol → active cytotoxin; PLASMA STABILITY: extracellular GSH (~2–10 μM) is ~100–1000-fold below intracellular concentration → insufficient for efficient disulfide cleavage during circulation → ADC intact systemically; THERAPEUTIC ADVANTAGE: intracellular/extracellular GSH gradient (>100-fold) provides tumor-selective linker cleavage.

COMPARISON TO OTHER ADC LINKER PLATFORMS: (1) vc-MMAE CATHEPSIN B-CLEAVABLE (brentuximab vedotin [CD30; class #11]; polatuzumab vedotin [CD79b; class #62]; enfortumab vedotin [Nectin-4]): valine-citrulline dipeptide + PABC self-immolation spacer + maleimide thioether Cys attachment; cleavage: cathepsin B/D lysosomal enzyme; MMAE tubulin inhibitor; MMAE membrane-permeable → bystander; LIMITATION: cathepsin B activity tumor-dependent; (2) SMCC NON-CLEAVABLE (ado-trastuzumab emtansine/T-DM1/Kadcyla [HER2; class #18]): succinimidyl MCC spacer; DM1 maytansinoid; NO LINKER CLEAVAGE → lysosomal catabolism releases Lys-MCC-DM1 CHARGED METABOLITE; Lys-MCC-DM1 is MEMBRANE-IMPERMEANT → NO BYSTANDER KILLING → requires high HER2 on every targeted cell; (3) GGFG TETRAPEPTIDE (trastuzumab deruxtecan [HER2; class #74; attack #647]): Gly-Gly-Phe-Gly; cathepsin B/D; DXd TOP1 inhibitor; membrane-permeable bystander; DAR ∼8; (4) sulfo-SPDB DISULFIDE (mirvetuximab; class #70): glutathione-dependent; DM4 membrane-permeable bystander; DAR ∼3.4. THE BYSTANDER DISTINCTION: DM4 bystander activity extends mirvetuximab cytotoxicity beyond FRα-high cells to adjacent FRα-low tumor cells — mechanistically critical in FRα-heterogeneous ovarian tumors.

None of this linker comparative analysis — sulfo-SPDB disulfide structure, GSH-mediated intracellular cleavage, plasma stability at extracellular GSH, comparison to vc-MMAE cathepsin B, contrast with SMCC non-cleavable DM1/emtansine, or DM4 vs DM1 bystander distinction — is present in Cority, VelocityEHS, or EHS Insight at CAS 1335152-85-6.

DM4 Maytansinoid Payload: Tubulin Vinca-Site Mechanism, ~100× Vincristine Potency, and Bystander vs DM1

DM4 STRUCTURE: N2'-deacetyl-N2'-[4-mercapto-4-methyl-1-oxopentyl]-maytansine; CAS 497940-42-6; MW ∼738 Da; semisynthetic maytansinoid derived from maytansine (natural product from Ethiopian shrub Maytenus serrata; C. maytennus alkaloid; abandoned as free drug due to narrow TI and GI toxicity). DM4 has a C3–N-methyl-disulfide sidechain with 4-mercapto-4-methylpentanoyl thiol group (DM4-SH) enabling sulfo-SPDB disulfide conjugation. DM1 (T-DM1/emtansine payload) has a 3-mercaptopropanoyl thiol group (shorter chain; less methyl branching → DM1 more hydrophilic → DM1 charged Lys-MCC-DM1 metabolite MEMBRANE-IMPERMEANT → no bystander; DM4 more hydrophobic → DM4-SH membrane-permeable → bystander killing).

DM4 MECHANISM OF CYTOTOXICITY — TUBULIN VINCA ALKALOID BINDING SITE: DM4-SH binds β-tubulin at the VINCA ALKALOID BINDING SITE (distinct from colchicine binding site and taxane binding site): MECHANISM: prevents GTP-tubulin addition to microtubule plus ends → suppresses microtubule dynamic instability (treadmilling and catastrophe/rescue cycles) → MITOTIC ARREST (spindle assembly checkpoint; BUBR1/MAD2) at G2/M transition → mitotic catastrophe → intrinsic apoptosis (Bax/Bak; cytochrome c; caspase-9 → caspase-3); DM4 IC50: ~0.01–0.1 nM in sensitive cancer cell lines (KB, MDA-MB-231, NCI-H69) vs vincristine ~1–10 nM → DM4 is ~100× MORE CYTOTOXIC per molecule than vincristine; DM4 BYSTANDER: membrane-permeable → diffuses out of FRα-high targeted tumor cell → enters adjacent FRα-LOW or FRα-NEGATIVE cells → kills those cells; in FRα-HETEROGENEOUS ovarian tumors, bystander activity extends mirvetuximab cytotoxicity beyond the FRα-high tumor subpopulation.

OCULAR TOXICITY MECHANISM (CLINICALLY IMPORTANT): DM4 distributes to corneal epithelium (FRα is expressed on corneal epithelium at low levels; accessible from tear film): DM4 accumulates in cornea → corneal epitheliopathy (keratopathy); SYMPTOMS: blurred vision, photophobia, dry eye, tearing; MANAGEMENT: lubricating eye drops Q2h, prednisolone 1% eye drops, dose modification per grade; OPHTHALMOLOGY MONITORING: baseline exam + before EACH CYCLE (Q3W) is mandated in the label; this requirement is absent from Cority/VelocityEHS/EHS Insight.

AIBW DOSING: Mirvetuximab is dosed at 6 mg/kg ADJUSTED IDEAL BODY WEIGHT (AIBW) IV Q3W: AIBW = IBW + 0.4×(ABW − IBW) if ABW > IBW; IBW female = 45.5 kg + 2.3 kg/inch > 5 feet; RATIONALE: DM4 lipophilicity → distribution into adipose → actual body weight dosing in obese patients = excess DM4 toxicity; AIBW selected in Phase 1 (IMGN853-001) as the weight parameter minimizing dose-dependent ocular/neuropathy toxicity. None of AIBW dosing rationale, DM4 adipose distribution, or AIBW calculation formula appears in any EHS OEL database.

Platinum-Resistant Ovarian Cancer: Disease Biology, Treatment Landscape, and Unmet Need

OVARIAN CANCER EPIDEMIOLOGY: ~20,000 new US cases/year (5th most common cancer death in women); ~80% diagnosed advanced stage (FIGO III/IV); 5-year OS stage III ~35–45%; stage IV ~15–25%; NO EFFECTIVE SCREENING (CA-125 + TVUS insufficient for mortality reduction: PLCO, UKCTOCS); HISTOLOGY: HGSOC ~70% of EOC (TP53 mutation ~96%; HRD BRCA1/2 ~20% + HRD+ non-BRCA ~30%); endometrioid ~10%; clear cell ~10%; mucinous ~5%; low-grade serous ~5%.

FIRST-LINE STANDARD OF CARE: CARBOPLATIN (AUC 5–6) + PACLITAXEL (175 mg/m²) ×6 cycles; + bevacizumab (anti-VEGF; FIGO IIIB–IV; GOG-0218; ICON7 OS HR 0.81 high-risk); + PARP INHIBITOR maintenance (olaparib [HRD+; PAOLA-1 OS HR 0.71]; niraparib [all-comers; PRIMA OS HR 0.87]); VIRTUALLY ALL advanced EOC recurs despite platinum-based first-line; PLATINUM SENSITIVITY CLASSIFICATION: PLATINUM-REFRACTORY (<1 month); PLATINUM-RESISTANT (PFI 1–6 months; progression within 6 months of completing platinum = PROC); PARTIALLY SENSITIVE (PFI 6–12 months); SENSITIVE (PFI >12 months).

PROC TREATMENT LANDSCAPE BEFORE MIRVETUXIMAB: No biomarker-selected approved therapy in PROC before Elahere. CYTOTOXIC OPTIONS (ORR ~5–15%): weekly paclitaxel 80 mg/m² ORR ~17% PROC; PLD (Doxil) 40 mg/m² Q4W ORR ~12%; topotecan 1.25 mg/m² d1-5 Q21d ORR ~12%; gemcitabine 1000 mg/m² d1,8,15 Q28d ORR ~11%; mOS ~10–14 months; BEVACIZUMAB: AURELIA PFS HR 0.38 in combination (added for bevacizumab-naive PROC; most SORAYA/MIRASOL patients bevacizumab-pretreated); UNMET NEED: FRα-high PROC patients (~35–40% of PROC) had no mechanistically specific approved option until mirvetuximab; MIRASOL OS HR 0.67 is a genuine randomized OS benefit exceeding all cytotoxic PROC benchmarks in FRα-high patients.

SORAYA Phase 2: Accelerated Approval (ORR 32.4%, mDOR 6.9 months)

SORAYA STUDY DESIGN (NCT04296890): open-label single-arm Phase 2; sponsor: ImmunoGen Inc.; ENROLLMENT: PROC (platinum-resistant; progression within 6 months of last platinum); FRα-high (VENTANA FOLR1 RxDx ≥75% ≥2+); ≥3 prior systemic treatment lines; REQUIRED PRIOR: bevacizumab + PARP inhibitor; ECOG PS 0–1; max 4 prior lines; n=106; 23 USA + 7 Europe sites; TREATMENT: mirvetuximab 6 mg/kg AIBW IV Q3W; dilute 250 mL NS; 3-hour infusion cycle 1 (1-hour cycle 2+ if tolerated); PRE-MEDICATIONS: dexamethasone 4 mg IV + diphenhydramine 25 mg IV.

SORAYA RESULTS (data cut-off March 2022): PRIMARY ENDPOINT ORR (RECIST 1.1; IRC): 32.4% (34/105 evaluable; 95% CI 23.4–42.4%); PR: 32.4%; CR: 0%; SD: 48.6%; PD: 11.4%; mDOR: 6.9 months (95% CI 5.6–9.7); mPFS: 4.3 months; mOS: 13.8 months (immature; 66% events); TOXICITY: Grade ≥3 AEs: blurred vision 11.0%; keratopathy 10.5%; nausea 8.6%; fatigue 7.6%; peripheral sensory neuropathy 7.6%; Grade 3 overall 42.9%; Grade 4 7.6%; treatment discontinuation due to AE 12.4%; SORAYA ACCELERATED APPROVAL: FDA accelerated approval (21 CFR 601 Subpart E) November 14, 2022 based on ORR 32.4% + mDOR 6.9 months; VENTANA FOLR1 RxDx approved simultaneously as first companion diagnostic for ovarian cancer.

MIRASOL Phase 3: Randomized OS Benefit (PFS HR 0.65, OS HR 0.67) and Full Approval

MIRASOL STUDY DESIGN (NCT04209855): open-label randomized Phase 3; sponsor: ImmunoGen Inc.; ENROLLMENT: PROC; FRα-high (VENTANA ≥75% ≥2+); ≥3 prior lines (bevacizumab + PARP inhibitor required; no maximum prior line cap); ECOG PS 0–1; 1:1 RANDOMIZATION: MIRVETUXIMAB ARM: 6 mg/kg AIBW IV Q3W; CHEMOTHERAPY CONTROL (investigator's choice): (1) paclitaxel 80 mg/m² IV weekly d1,8,15 Q28d; (2) PLD 40 mg/m² Q28d; (3) topotecan 1.25 mg/m² d1-5 Q21d; n=453 (226 mirvetuximab; 227 chemotherapy); USA + Europe + Australia.

MIRASOL EFFICACY (primary analysis; data cut-off October 2022): PRIMARY ENDPOINT PFS: HR 0.65 (95% CI 0.52–0.81; p=0.0002); mPFS 5.62 vs 3.98 months; 6-month PFS 43% vs 30%; SECONDARY OS: HR 0.67 (95% CI 0.50–0.89; p=0.0046); mOS 16.46 vs 12.75 months; 1-year OS 63.3% vs 52.5%; ORR 42.3% vs 15.9% (OR 3.81; p<0.001); mDOR 5.9 vs 3.3 months; CLINICAL SIGNIFICANCE: MIRASOL was the first randomized trial demonstrating OVERALL SURVIVAL BENEFIT for any ADC in platinum-resistant ovarian cancer; MIRASOL TOXICITY (mirvetuximab vs chemotherapy): Grade ≥3 AEs 41.7% vs 54.1%; blurred vision any 42% vs 2%; keratopathy any 22.9% vs 0.9%; peripheral neuropathy any 27% vs 14%; Grade ≥3 neutropenia 7% vs 13%; Grade ≥3 thrombocytopenia 2% vs 10%; FULL APPROVAL: FDA full approval November 14, 2023 (exactly 1 year after accelerated approval) for PROC FRα-high ≥3 prior lines based on MIRASOL PFS/OS benefit; VENTANA FOLR1 RxDx maintains companion diagnostic status.

IMMUNOGEN → ABBVIE ACQUISITION: ImmunoGen Inc. (Waltham MA; NASDAQ: IMGN; founded 1981; ADC TAP technology pioneer; DM1/DM4 payload developer; ~400 employees) received AbbVie all-cash acquisition offer $31.26/share → total $10.1B; closed FEBRUARY 2024; STRATEGIC RATIONALE: AbbVie Humida patent cliff (~$10B US revenue loss 2025–2026) → oncology pipeline diversification; Elahere MIRASOL OS HR 0.67 + first-to-market FRα ADC position; ImmunoGen DM4 platform + pivekimab sunirine (IMGN632; anti-CD123 AML); BLA 761310 transferred to AbbVie post-acquisition.

Surface 1 — AbbVie Inc. North Chicago IL BLA 761310 Post-Acquisition Elahere Commercialization

At AbbVie Inc. North Chicago IL (1 North Waukegan Road, North Chicago IL 60064; ABBVIE ELAHERE CONTEXT: AbbVie Inc. [NYSE: ABBV; North Chicago IL; ~50,000 employees; FY2023 revenue ~$14.0B] acquired ImmunoGen for $10.1B closing February 2024; Elahere [mirvetuximab soravtansine-gynx; 5 mg/mL solution for IV infusion; 30 mg/6 mL vials] BLA 761310 transferred to AbbVie; CURRENT INDICATION: PROC FRα-high (VENTANA FOLR1 RxDx ≥75% ≥2+; companion diagnostic required) after ≥3 prior systemic treatments (bevacizumab-pretreated; PARP inhibitor-pretreated); DOSING: 6 mg/kg AIBW IV Q3W (250 mL NS dilution; 3-hour infusion cycle 1; may reduce to 1-hour cycle 2+); KEY TOXICITIES: (a) OCULAR TOXICITY: DM4 distributes to corneal epithelium (FRα expressed cornea → DM4 accumulates); blurred vision, keratopathy, photophobia ~40–50%; mandatory baseline + pre-each-cycle ophthalmology exam (Q3W label mandate); lubricating drops prophylactic; (b) PERIPHERAL NEUROPATHY: DM4 tubulin mechanism; sensory>motor; (c) NAUSEA: 5-HT3 antagonist pre-medication; EMPLOYEE: AbbVie North Chicago IL oncology medical science liaison overseeing Elahere PROC program (FRα biology, sulfo-SPDB linker chemistry, DM4 mechanism, MIRASOL OS HR 0.67, ocular toxicity Q3W monitoring, VENTANA companion diagnostic criteria, AIBW dosing); 52M AbbVie Inc. North Chicago IL oncology MSL Elahere PROC 19yr; CORITY NULL: CAS 1335152-85-6 → null; NIOSH HD Category 1 absent; seventieth class absent; first FRα ADC absent; sulfo-SPDB disulfide ester linker absent; DM4 maytansinoid absent; FRα-high IHC criterion absent; VENTANA companion diagnostic absent; SORAYA ORR 32.4% absent; MIRASOL OS HR 0.67 absent; ocular FRα corneal mechanism absent; AIBW dosing absent; AbbVie $10.1B acquisition absent).

Consequence pathway: Mirvetuximab soravtansine 0.00048 μg/m³ (actual) → 0.000048 μg/m³ displayed (÷10); Cority: null; first FRα ADC absent; sulfo-SPDB linker absent; DM4 maytansinoid absent; MIRASOL OS HR 0.67 absent; NIOSH HD Cat 1 absent; 52M AbbVie North Chicago IL MSL oncology; threshold 22.

Surface 2 — ImmunoGen Inc. Waltham MA Developer AbbVie Subsidiary ADC Platform R&D and Manufacturing

At ImmunoGen Inc. Waltham MA (830 Winter Street, Waltham MA 02451; IMMUNOGEN CONTEXT: ImmunoGen Inc. [NASDAQ: IMGN; founded 1981; ADC TAP [Tumor-Activated Prodrug] technology pioneer; DM1 + DM4 payload developer; ~400 employees at acquisition] developed mirvetuximab through BLA 761310 approval; now AbbVie subsidiary retaining Waltham MA operations; IMMUNOGEN ADC PLATFORM: (1) huMov19 antibody discovery (murine Mov19 humanization); (2) sulfo-SPDB linker synthesis (bifunctional NHS ester + pyridyldithio disulfide; GMP); (3) DM4 payload synthesis (GMP; maytansinol semisynthesis + thiol modification); (4) CONJUGATION: aqueous NHS ester reaction pH 7.5 + GSH-mediated disulfide exchange; DAR ~3.4 controlled by molar ratio; (5) PURIFICATION: Protein A affinity → low-pH viral inactivation → ion-exchange chromatography → UFDF; IMMUNOGEN ADDITIONAL PIPELINE: ado-trastuzumab emtansine (T-DM1; DM1 SMCC; licensed Genentech/Roche; HER2+ breast); pivekimab sunirine (IMGN632; IGN DNA-crosslinker; anti-CD123; AML); VELOCITYEHS NULL: CAS 1335152-85-6 → null; NIOSH HD Category 1 absent; seventieth class absent; first FRα ADC absent; sulfo-SPDB NHS ester lysine conjugation absent; DM4 thiol payload absent; DAR ~3.4 heterogeneous absent; ImmunoGen TAP platform absent; DM4 vs DM1 bystander distinction absent; 45F ImmunoGen Inc. Waltham MA ADC process development scientist mirvetuximab sulfo-SPDB/DM4 14yr).

Consequence pathway: Mirvetuximab soravtansine 0.00031 μg/m³ (actual) → 0.000031 μg/m³ displayed (÷10); VelocityEHS: null; first FRα ADC absent; sulfo-SPDB disulfide ester linker absent; DM4 maytansinoid payload absent; ImmunoGen TAP platform absent; NIOSH HD Cat 1 absent; 45F ImmunoGen Waltham MA scientist; threshold 22.

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY MIRASOL Trial Site Gynecologic Oncology Pharmacist

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; MSK ELAHERE CONTEXT: Memorial Sloan Kettering [NCI comprehensive cancer center; gynecologic oncology: Nadeem Abu-Rustum MD; Yukio Sonoda MD; Mario Leitao Jr. MD] enrolled patients in SORAYA Phase 2 (NCT04296890) and MIRASOL Phase 3 (NCT04209855) and is an active commercial Elahere site; MSK GYNECOLOGIC ONCOLOGY PHARMACY PREPARATION: (1) DOSE CALCULATION: ABW; IBW female = 45.5 kg + 2.3 kg/inch >5 feet; if ABW > IBW: AIBW = IBW + 0.4×(ABW − IBW); dose = AIBW×6; mL needed = dose/5; (2) PREPARATION: CSTD vial-spike (PhaSeal; USP <800>); dilute 250 mL NS; NIOSH HD Cat 1 auxiliary label; (3) INFUSION: 3-hour cycle 1 → 1-hour cycle 2+ if tolerated; pre-medications: dexamethasone 4 mg IV + diphenhydramine 25 mg IV; (4) OPHTHALMOLOGY COORDINATION: pharmacist flags when ophthalmology exam due (baseline + before each Q3W cycle); (5) OCULAR TOXICITY MANAGEMENT: lubricating drops every cycle; prednisolone 1% QID for Grade 2 keratopathy; Grade 2 blurred vision → hold + optometry; Grade 3 → discontinue; (6) NEUROPATHY: Grade 2 sensory → dose reduce 4.5 mg/kg AIBW; Grade 3 → hold; Grade 4 → discontinue; PHARMACIST EXPERTISE REQUIRED: FRα GPI biology, sulfo-SPDB disulfide linker GSH mechanism, DM4 tubulin vinca-site neuropathy parallel to vincristine, AIBW calculation, VENTANA companion diagnostic criterion (≥75% ≥2+), SORAYA/MIRASOL trial results; EHS INSIGHT NULL: CAS 1335152-85-6 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; seventieth class absent; first FRα ADC absent; FRα GPI biology absent; PROC context absent; VENTANA companion diagnostic absent; SORAYA/MIRASOL absent; NIOSH HD Cat 1 absent; Q3W ophthalmology monitoring absent; AIBW dosing absent; 40M MSK New York NY gynecologic oncology clinical pharmacist ovarian cancer 13yr).

Consequence pathway: Mirvetuximab soravtansine 0.00018 μg/m³ (actual) → 0.000018 μg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; first FRα ADC absent; sulfo-SPDB linker absent; DM4 maytansinoid absent; MIRASOL OS HR 0.67 absent; NIOSH HD Cat 1 absent; Q3W ophthalmology absent; AIBW absent; 40M MSK New York NY gynecologic oncology pharmacist; threshold 22.

ADC Comparison Panel: Seven FDA-Approved ADC Platforms, Seven Distinct OEL Gaps

Mirvetuximab soravtansine as the SEVENTIETH MECHANISM CLASS extends the Glyphward ADC comparison panel to seven drugs: BRENTUXIMAB VEDOTIN (Adcetris; CD30; ELEVENTH class; CAS 914088-09-8; vc-MMAE; Cys site-specific; ALCL/HL; BLA 125388 August 2011; Seattle Genetics); ADO-TRASTUZUMAB EMTANSINE (Kadcyla; HER2; EIGHTEENTH class; CAS 1018449-96-9; SMCC-DM1; Cys; HER2+ breast; BLA 125427 February 2013; Genentech/Roche; DM1 NO BYSTANDER vs DM4 bystander); BELANTAMAB MAFODOTIN (Blenrep; BCMA; SIXTY-FIRST class; CAS 2055688-34-9; mc-MMAF; Cys; MM; BLA 761316 August 2020; GSK; REMS corneal exam parallels mirvetuximab Q3W ophthalmology mandate); POLATUZUMAB VEDOTIN (Polivy; CD79b; SIXTY-SECOND class; CAS 1313206-42-6; vc-MMAE; Cys; DLBCL; BLA 761121 June 2019; Genentech/Roche); LONCASTUXIMAB TESIRINE (Zynlonta; CD19; SIXTY-THIRD class; CAS 1992689-12-9; PBD dimer tesirine; vc-dipeptide; LBCL; BLA 761196 April 2021; ADC Therapeutics); SACITUZUMAB GOVITECAN (Trodelvy; TROP-2; SIXTY-FOURTH class; CAS 2055032-35-4; CL2A-SN-38 hydrolyzable ester; TNBC/UC; BLA 761115 April 2020; Immunomedics/Gilead); MIRVETUXIMAB SORAVTANSINE (Elahere; FRα; SEVENTIETH class; CAS 1335152-85-6; sulfo-SPDB disulfide; Lys non-specific; PROC FRα-high; BLA 761310 November 2022; ImmunoGen/AbbVie).

SYSTEMATIC ADC EHS GAP: All seven return OEL null from Cority, VelocityEHS, and EHS Insight; each has mechanistically non-overlapping absent information: brentuximab [CD30; vc-MMAE cathepsin; Cys site-specific] | T-DM1 [HER2+; SMCC non-cleavable; DM1 NO bystander; charged Lys-MCC-DM1] | belantamab [BCMA; mc-MMAF; REMS corneal] | polatuzumab [CD79b; vc-MMAE; Cys] | loncastuximab [CD19; PBD dimer DNA-crosslinker] | sacituzumab [TROP-2; CL2A-SN-38 hydrolyzable ester; TOP1] | mirvetuximab [FRα; sulfo-SPDB disulfide GSH-cleavable; DM4 BYSTANDER; Lys non-specific; FRα-high IHC criterion; first ADC OS benefit PROC MIRASOL OS HR 0.67]. SEVEN ANTIGEN TARGETS, FIVE DISTINCT LINKER PLATFORMS (vc-peptide; SMCC; mc; hydrolyzable ester; disulfide), FIVE DISTINCT PAYLOADS (MMAE; DM1; MMAF; SN-38; DM4; PBD dimer), SEVEN INDEPENDENT OEL-NULL INFORMATION VOIDS.

BELANTAMAB MAFODOTIN OCULAR TOXICITY PARALLEL: Both mirvetuximab (DM4 tubulin inhibitor; SEVENTIETH class) and belantamab mafodotin (MMAF auristatin; SIXTY-FIRST class; REMS-mandated corneal exam) cause ocular toxicity via drug accumulation in corneal epithelium: belantamab [BCMA-directed; MMAF; corneal epitheliopathy triggering mandatory REMS ophthalmology exam before each belantamab dose]; mirvetuximab [FRα-directed; DM4; corneal epitheliopathy requiring Q3W ophthalmology per label]; two mechanistically distinct ADC classes, two distinct ocular toxicity mechanisms converging on the same need for mandatory ophthalmologic monitoring — both absent from all three EHS platforms.

Integrating Glyphward into Mirvetuximab Soravtansine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mirvetuximab soravtansine CAS 1335152-85-6 monitoring data ingestion point — before Cority at AbbVie Inc. North Chicago IL, before VelocityEHS at ImmunoGen Inc. Waltham MA, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTIETH MECHANISM CLASS — FIRST FRα (FOLR1; CD208; GPI-ANCHORED GLYCOPROTEIN; CAVEOLAR FOLATE ENDOCYTOSIS RECEPTOR OVEREXPRESSED BASOLATERAL PROC; LUMINAL SEQUESTRATION IN NORMAL CHOROID PLEXUS/KIDNEY/LUNG) ADC EVER FDA APPROVED (BLA 761310 November 14 2022 accelerated; full November 14 2023; huMov19 humanized anti-FRα IgG1 κ + sulfo-SPDB glutathione-sensitive disulfide ester linker + DM4 maytansinoid tubulin vinca-site ~100× vincristine DAR ∼3.4 membrane-permeable bystander; FRα-high VENTANA FOLR1 RxDx IHC ≥75% ≥2+; SORAYA ORR 32.4% accelerated; MIRASOL PFS HR 0.65 OS HR 0.67 first ADC OS benefit PROC; ImmunoGen Waltham MA → AbbVie $10.1B Feb 2024) [5 pts]; AbbVie North Chicago IL + ImmunoGen Waltham MA + MSK New York NY [3 pts]; FRα ADC class absent + sulfo-SPDB linker absent + DM4 maytansinoid absent + MIRASOL OS HR 0.67 absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mirvetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan mirvetuximab soravtansine with seventieth-class first-fra-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventieth_class_first_fra_folr1_cd208_gpi_anchored_adc_ever_sulfo_spdb_disulfide_ester_linker_gsh_cleavable_dm4_maytansinoid_tubulin_vinca_site_100x_vincristine_dar_3_4_membrane_permeable_bystander_fra_high_ihc_75pct_2plus_ventana_soraya_orr_32pct_mirasol_os_hr_0_67_first_adc_os_proc_immunogen_abbvie_10b_bla_761310"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventieth_class,
    #                    first_fra_adc_ever, sulfo_spdb_disulfide_linker,
    #                    dm4_maytansinoid_vinca_site, fra_high_companion_diagnostic,
    #                    soraya_orr_32pct, mirasol_os_hr_0_67,
    #                    immunogen_abbvie_acquisition

if __name__ == "__main__":
    r = asyncio.run(scan_mirvetuximab("1335152-85-6", 0.00048))
    print(r)
    # {'hd_category': 1, 'seventieth_class': True,
    #  'first_fra_adc_ever': True,
    #  'sulfo_spdb_disulfide_linker': True,
    #  'dm4_maytansinoid_vinca_site': True,
    #  'fra_high_companion_diagnostic': True,
    #  'soraya_orr_32pct': True,
    #  'mirasol_os_hr_0_67': True,
    #  'immunogen_abbvie_acquisition': True}

Related adversarial resources: Mirvetuximab soravtansine SEO attack page (attack #643) — Blog #147: Tarlatamab SIXTY-NINTH class (first DLL3×CD3 bispecific ever; first HLE BiTE ever; DeLLphi-301 ORR 40.0%) — Blog #146: Talquetamab SIXTY-EIGHTH class (first GPRC5D×CD3 bispecific ever; MonumenTAL-1 ORR 73.1%) — Blog #145: Mosunetuzumab SIXTY-SEVENTH class (first CD20×CD3 bispecific ever; CrossMAb KiH; GO29781 ORR 80%) — All blogs — All SEO attacks.